Psoriatic arthritis: current therapy and future directions.

Item

http://www.wikidata.org/entity/Q38118343

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Psoriatic arthritis: current therapy and future directions.

@en

type

Item

label

Psoriatic arthritis: current therapy and future directions.

@en

prefLabel

Psoriatic arthritis: current therapy and future directions.

@en

P1476

Psoriatic arthritis: current therapy and future directions.

@en

P2093

Arthur Kavanaugh

http://www.w3.org/2001/XMLSchema#string

DoQuyen Huynh

http://www.w3.org/2001/XMLSchema#string

P2860

Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT)

Comparison of effectiveness and safety of infliximab, etanercept, and adalimumab in psoriatic arthritis patients who experienced an inadequate response to previous disease-modifying antirheumatic drugs.

Rituximab treatment for spondyloarthritis. A nationwide series: data from the AIR registry of the French Society of Rheumatology.

A randomised, double blind, placebo controlled, multicentre trial of combination therapy with methotrexate plus ciclosporin in patients with active psoriatic arthritis.

Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial.

Detailed analysis of the cell infiltrate and the expression of mediators of synovial inflammation and joint destruction in the synovium of patients with psoriatic arthritis: implications for treatment

Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment: results from the IMPACT 2 trial.

Infliximab plus methotrexate is superior to methotrexate alone in the treatment of psoriatic arthritis in methotrexate-naive patients: the RESPOND study.

Ectopic lymphoid neogenesis in psoriatic arthritis.

A randomized placebo-controlled trial of methotrexate in psoriatic arthritis

P304

1755-1764

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14656566.2013.810208

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2013-07-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23815157

http://www.w3.org/2001/XMLSchema#string